Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Keratosis, Actinic 10Condylomata Acuminata 3Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Neoplasms 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Exanthema 1Carcinoma, Non-Small-Cell Lung 1Acne Vulgaris 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × Gels × Clear all
NCT00343187 2011-05-30

A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

Allergan

Phase 2 Terminated
2 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡